Neogen (NEOG) Competitors

Haemonetics (NYSE:HAE) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Which has more volatility and risk, HAE or NEOG?

Haemonetics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Neogen has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Do analysts recommend HAE or NEOG?

Haemonetics presently has a consensus price target of $97.30, suggesting a potential upside of 23.24%. Neogen has a consensus price target of $7.50, suggesting a potential upside of 32.67%. Given Neogen's higher possible upside, analysts plainly believe Neogen is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Neogen	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do institutionals and insiders hold more shares of HAE or NEOG?

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by insiders. Comparatively, 1.1% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media prefer HAE or NEOG?

In the previous week, Haemonetics had 2 more articles in the media than Neogen. MarketBeat recorded 9 mentions for Haemonetics and 7 mentions for Neogen. Haemonetics' average media sentiment score of 1.27 beat Neogen's score of 0.06 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has better earnings & valuation, HAE or NEOG?

Haemonetics has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.36B	2.79	$167.68M	$3.31	23.85
Neogen	$906.00M	1.35	-$9.42M	-$2.23	-2.53

Is HAE or NEOG more profitable?

Haemonetics has a net margin of 12.32% compared to Neogen's net margin of -53.56%. Haemonetics' return on equity of 26.37% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	12.32%	26.37%	9.22%
Neogen	-53.56%	2.69%	1.82%

Summary

Haemonetics beats Neogen on 15 of the 17 factors compared between the two stocks.